DCF FV $478 vs $190 stock (P(above)=98.7%), PE 8.2x, 31% analyst upside. Medicaid reform headwind ($432-480M/yr) is 2028-2032 — 6yr runway. Market pricing existential risk that is unlikely. Clear upside asymmetry.
Fair Value Distribution — percentile bands
98.7% of simulations place fair value above current price
WHAT IS PRICED IN
Revenue-Based Reverse DCF
-5.4%/yr
±4.5% · revenue growth to justify current price
FCF-Based Reverse DCF
11.8%/yr
±2.8% · FCF growth to justify current price
THE GAP
Market pricing margin compression or rising capex
KEY VALUE DRIVERS
Spearman correlation — what moves this valuation most
Eagle will generate this view by the next trading session (~6h).
Eagle will generate this view by the next trading session (~6h).
Medicaid reform legislation creates $432-480M annual headwind by 2032. Litigation tail risk material (Cumberland + Pinnacle). Geographic concentration elevated. Behavioral health segment more attracti...